$NVO — what investors on X are saying

$NVONovo Nordisk A/S · Drug Manufacturers - General · $171B

$38.44

-1.0%

Event thread

Key events, in time order

30 items

2026-10-02 → 10-05RegulationBear
FDA Delays Denecimig Review on Facility Remediation; Novo Hemophilia Drug Launch Pushed Back
Delay due to manufacturing remediation, not clinical efficacy/safety issues; timeline impacted
D1 -0.2% · +5d +3.5%
2 waves of this story
- 2026-10-02 FDA says review ongoing, approval timeline uncertain, impacting hemophilia pipeline outlook
- 2026-10-05 Delay due to manufacturing remediation, not clinical efficacy/safety issues; timeline impacted
2026-10-03ProductBear
Lilly Oral Data Adds Pressure; Novo Nordisk Faces Intensified Obesity Competition
Lilly's mid-stage data shows better weight loss than tirzepatide, pressuring Novo's oral obesity franchise
D1 +0.6% · +5d +2.8%

28 earlier events

2026-09-29 → 10-01ProductBull
Novo's Ozempic 2mg Shows Lower CV Risk vs Mounjaro
COMPETE SWITCH study shows 6% lower MACE risk vs Mounjaro
D1 -1.0% · +5d -2.0%
2 waves of this story
- 2026-09-29 Real-world evidence supports higher Ozempic dose, potentially impacting GLP-1 competitive dynamics
- 2026-10-01 COMPETE SWITCH study shows 6% lower MACE risk vs Mounjaro
2026-09-29Company
Novo Nordisk inks up to $2.6B licensing deal with Hengrui for oral obesity drug
Adds phase 1-ready once-weekly oral GLP-1/GIP dual agonist to bolster obesity pipeline amid competition
D1 -1.0% · +5d -2.0%
2026-09-25CompanyBull
Novo Nordisk signs $1.3B licensing deal with Nanexa for injection tech
Technology could cut injection frequency for obesity and diabetes drugs, boosting NVO's pipeline
D1 +0.5% · +5d -3.8%
2026-09-24RegulationBull
Novo Nordisk Receives Positive EU Regulatory Recommendations, Expanding Rare Disease Pipeline
Positive CHMP opinions for Frehemgo and Sogroya, potentially diversifying revenue
D1 +1.2% · +5d -3.2%
2026-09-23Company
Novo CEO: Pills could capture 50% of weight-loss market by 2030
CEO's outlook underscores oral strategy amid Lilly competition and patent cliff
D1 -3.1% · +5d -0.7%
2026-09-23Capital
CEO Open to Direct NYSE Listing to Boost US Presence
US accounts for over half of revenue; direct listing may increase visibility
D1 -3.1% · +5d -0.7%
2026-09-21ProductBull
Novo Nordisk's CagriSema Shows Superior Weight Loss vs Tirzepatide in Phase 5 Trial
CagriSema achieved 12.4% weight loss vs 9.1% for tirzepatide in REIMAGINE 5 trial.
D1 -8.0% · +5d -2.7%
2026-09-17 → 09-19RegulationBull
Novo's Denecimig Gets EU CHMP Positive Opinion
EU regulator backs hemophilia A treatment, potentially expanding Novo's portfolio
D1 +3.5% · +5d -10.6%
2 waves of this story
- 2026-09-17 Key regulatory nod advances hemophilia pipeline amid competition and patent pressures
- 2026-09-19 EU regulator backs hemophilia A treatment, potentially expanding Novo's portfolio
2026-09-17Company
Novo Nordisk partners with Anthropic for AI-driven drug discovery
Deploys frontier AI models across R&D and software engineering to speed drug development
D1 +3.5% · +5d -10.6%
2026-09-17CapitalBull
Novo Nordisk, Orbis Sign Up to $1.4B Oral Drug Deal
Expands oral macrocyclic peptide therapies, bolstering cardiometabolic pipeline
D1 +3.5% · +5d -10.6%
2026-09-16ProductBear
Lilly's Oral GLP-1 Captures 30%+ New US Patients, Pressuring Novo's Oral Share
Lilly claims 30%+ of new US oral GLP-1 patients; Novo's Wegovy pill previously held ~90% of US oral obesity market
D1 -1.9% · +5d -8.5%
2026-09-14 → 09-15CompanyBear
Novo Nordisk Rebrands to Novo; CEO Urges Customer Focus, Shares Fall 2%
CEO pushes customer-centric culture post-rebrand; analyst says move fails to ease competition and pricing headwinds
D1 +0.9% · +5d -8.4%
2 waves of this story
- 2026-09-14 Day-to-day name changes to Novo to boost recognition amid obesity market share loss.
- 2026-09-15 CEO pushes customer-centric culture post-rebrand; analyst says move fails to ease competition and pricing headwinds
2026-09-12 → 09-14AnalystBear
Morgan Stanley downgrades Novo to Underweight on patent, rivalry woes
MS cuts to Underweight citing muted growth, patent risks, Lilly pressure.
D1 +0.9% · +5d -8.4%
2 waves of this story
- 2026-09-12 Analysts worry semaglutide to be 75% of 2026 sales, patent cliff looms
- 2026-09-14 MS cuts to Underweight citing muted growth, patent risks, Lilly pressure.
2026-09-11Analyst
Morgan Stanley downgrades to Underweight
D1 -2.1% · +5d +0.4%
2026-09-10ProductBull
Novo Nordisk's Wegovy approved in China for MASH liver disease
First GLP-1 approved in China for MASH, expanding Wegovy's indications
D1 -1.2% · +5d -1.9%
2026-09-07 → 09-09Product
Novo's Semaglutide Hits Pediatric Obesity Goal Amid Competitive Pressures
Phase III STEP Young shows BMI reduction in obese children aged 6-12, 40.4% no longer obese; faces Lilly competition and patent cliffs
D1 -3.1% · +5d -5.8%
2 waves of this story
- 2026-09-07 Two independent reports confirm primary endpoint met in children 6-12, potentially expanding Wegovy's label
- 2026-09-09 Phase III STEP Young shows BMI reduction in obese children aged 6-12, 40.4% no longer obese; faces Lilly competition and patent cliffs
2026-09-08CompanyBear
Novo Nordisk halts two more heart drug trials, diversification setback
Two ziltivekimab trials halted, underscoring reliance on obesity franchise for growth
D1 -3.1% · +5d -5.8%
2026-09-02 → 09-03Regulation
FDA Warns on Compounded GLP-1 Risks, Novo Nordisk in Focus
FDA cites 30 firms, HIMS falls, LLY and NVO in focus
D1 +3.7% · +5d -5.9%
2 waves of this story
- 2026-09-02 FDA warning letters ban retatrutide and cagrilintide in compounding, impacting GLP-1 market
- 2026-09-03 FDA cites 30 firms, HIMS falls, LLY and NVO in focus
2026-09-01 → 09-03Product
Novo Nordisk's Oral Wegovy Launches in Germany, Zava Begins Delivery
Zava confirms delivery of oral Wegovy in Germany, aligning with EU-first launch and advancing commercialization
D1 -0.5% · +5d -1.2%
2 waves of this story
- 2026-09-01 Oral Wegovy launched in Germany, first EU country, expanding weight-loss drug market reach
- 2026-09-03 Zava confirms delivery of oral Wegovy in Germany, aligning with EU-first launch and advancing commercialization
2026-08-28AnalystBear
Deutsche Bank downgrades Novo Nordisk to Sell, shares down 70% from peak
Growth concerns mount; Wall Street had been reluctant to advise selling
D1 -1.4% · +5d +2.2%
2026-08-14 → 08-26Product
China regulator accepts oral Wegovy application; competition persists
After Lilly oral approval, Novo advances oral weight-loss drug in China
D1 -1.8% · +5d +1.9%
2 waves of this story
- 2026-08-14 Eli Lilly's Foundayo, Europe's first oral GLP-1 approval with no food restrictions, directly challenges Novo Nordisk's oral Wegovy
- 2026-08-26 After Lilly oral approval, Novo advances oral weight-loss drug in China
2026-08-10 → 08-19Company
Novo Nordisk Starts Study for Lowest Effective Wegovy Pill Dose
New study tests lower doses, potentially expanding oral weight-loss drug access
D1 +1.0% · +5d -6.0%
4 waves of this story
- 2026-08-10 Co-innovation hub in London to accelerate drug discovery
- 2026-08-11 Oral GLP-1 competition intensifies; OASIS 5 start and UK approval of Lilly's pill both impact NVO's market position
- 2026-08-11 Phase 3 trial for oral weight-loss drug expands pipeline amid competitive pressure.
- 2026-08-19 New study tests lower doses, potentially expanding oral weight-loss drug access
2026-08-12AnalystBear
Berenberg Cuts Novo Nordisk to Hold, PT Lowered to $47
Analyst sees further multiple expansion requiring proof of obesity-pill lead and injectable growth
D1 -1.7% · +5d +0.2%
2026-08-11CapitalBear
First Trust Advisors Cuts Novo Nordisk Stake by 94.5% in Q1
Institutional selling signals caution on Novo Nordisk's near-term outlook.
D1 -1.2% · +5d -3.1%
2 waves of this story
- 2026-08-11 Institutional 13F filing shows major stake reduction, reflecting institutional flows
- 2026-08-11 Institutional selling signals caution on Novo Nordisk's near-term outlook.
2026-08-08ProductBear
Eli Lilly Officially Sets Q1 2027 FDA Filing for Retatrutide, Intensifying Weight-Loss Competition
Lilly reports 28.3% average weight loss over 80 weeks in phase 3, with official filing timeline, directly pressuring Novo Nordisk
D1 +1.0% · +5d -6.0%
2 waves of this story
- 2026-08-08 Phase 3 shows 28.3% avg weight loss, outperforming rivals, posing direct threat to Novo Nordisk
- 2026-08-08 Lilly reports 28.3% average weight loss over 80 weeks in phase 3, with official filing timeline, directly pressuring Novo Nordisk
2026-08-05 → 08-08Earnings
Novo Nordisk Q2: Adjusted Sales Up 7%, GLP-1 Volume Supports but Prices Under Pressure
Earnings call reveals latest results, completing the event line with prior guidance and stock reaction
D1 +0.6% · +5d +4.2%
3 waves of this story
- 2026-08-05 Q2 profit beat and guidance hike failed to reassure, as Wegovy pill sales slightly missed and pipeline concerns persist, sending shares down over 5%.
- 2026-08-05 CEO Doustdar pledges faster R&D and bolt-on acquisitions, but investors remain cautious on pipeline confidence.
- 2026-08-08 Earnings call reveals latest results, completing the event line with prior guidance and stock reaction
2026-08-07RegulationBull
Texas Court Dismisses Strive Antitrust Suit Against Novo and Lilly
Federal judge dismisses Strive antitrust suit; NVO rises nearly 2%
D1 +2.8% · +5d -2.9%
2 waves of this story
- 2026-08-07 Court found no proof of blocked competition, easing legal overhang for Novo and Lilly.
- 2026-08-07 Federal judge dismisses Strive antitrust suit; NVO rises nearly 2%
2026-08-05Earnings
Earnings report
D1 +0.6% · +5d +4.2%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

30 items

2026-10-02 → 10-05RegulationBear
FDA Delays Denecimig Review on Facility Remediation; Novo Hemophilia Drug Launch Pushed Back
Delay due to manufacturing remediation, not clinical efficacy/safety issues; timeline impacted
D1 -0.2% · +5d +3.5%
2 waves of this story
- 2026-10-02 FDA says review ongoing, approval timeline uncertain, impacting hemophilia pipeline outlook
- 2026-10-05 Delay due to manufacturing remediation, not clinical efficacy/safety issues; timeline impacted
2026-10-03ProductBear
Lilly Oral Data Adds Pressure; Novo Nordisk Faces Intensified Obesity Competition
Lilly's mid-stage data shows better weight loss than tirzepatide, pressuring Novo's oral obesity franchise
D1 +0.6% · +5d +2.8%
2026-09-29 → 10-01ProductBull
Novo's Ozempic 2mg Shows Lower CV Risk vs Mounjaro
COMPETE SWITCH study shows 6% lower MACE risk vs Mounjaro
D1 -1.0% · +5d -2.0%
2 waves of this story
- 2026-09-29 Real-world evidence supports higher Ozempic dose, potentially impacting GLP-1 competitive dynamics
- 2026-10-01 COMPETE SWITCH study shows 6% lower MACE risk vs Mounjaro
2026-09-29Company
Novo Nordisk inks up to $2.6B licensing deal with Hengrui for oral obesity drug
Adds phase 1-ready once-weekly oral GLP-1/GIP dual agonist to bolster obesity pipeline amid competition
D1 -1.0% · +5d -2.0%
2026-09-25CompanyBull
Novo Nordisk signs $1.3B licensing deal with Nanexa for injection tech
Technology could cut injection frequency for obesity and diabetes drugs, boosting NVO's pipeline
D1 +0.5% · +5d -3.8%

25 earlier events

2026-09-24RegulationBull
Novo Nordisk Receives Positive EU Regulatory Recommendations, Expanding Rare Disease Pipeline
Positive CHMP opinions for Frehemgo and Sogroya, potentially diversifying revenue
D1 +1.2% · +5d -3.2%
2026-09-23Company
Novo CEO: Pills could capture 50% of weight-loss market by 2030
CEO's outlook underscores oral strategy amid Lilly competition and patent cliff
D1 -3.1% · +5d -0.7%
2026-09-23Capital
CEO Open to Direct NYSE Listing to Boost US Presence
US accounts for over half of revenue; direct listing may increase visibility
D1 -3.1% · +5d -0.7%
2026-09-21ProductBull
Novo Nordisk's CagriSema Shows Superior Weight Loss vs Tirzepatide in Phase 5 Trial
CagriSema achieved 12.4% weight loss vs 9.1% for tirzepatide in REIMAGINE 5 trial.
D1 -8.0% · +5d -2.7%
2026-09-17 → 09-19RegulationBull
Novo's Denecimig Gets EU CHMP Positive Opinion
EU regulator backs hemophilia A treatment, potentially expanding Novo's portfolio
D1 +3.5% · +5d -10.6%
2 waves of this story
- 2026-09-17 Key regulatory nod advances hemophilia pipeline amid competition and patent pressures
- 2026-09-19 EU regulator backs hemophilia A treatment, potentially expanding Novo's portfolio
2026-09-17Company
Novo Nordisk partners with Anthropic for AI-driven drug discovery
Deploys frontier AI models across R&D and software engineering to speed drug development
D1 +3.5% · +5d -10.6%
2026-09-17CapitalBull
Novo Nordisk, Orbis Sign Up to $1.4B Oral Drug Deal
Expands oral macrocyclic peptide therapies, bolstering cardiometabolic pipeline
D1 +3.5% · +5d -10.6%
2026-09-16ProductBear
Lilly's Oral GLP-1 Captures 30%+ New US Patients, Pressuring Novo's Oral Share
Lilly claims 30%+ of new US oral GLP-1 patients; Novo's Wegovy pill previously held ~90% of US oral obesity market
D1 -1.9% · +5d -8.5%
2026-09-14 → 09-15CompanyBear
Novo Nordisk Rebrands to Novo; CEO Urges Customer Focus, Shares Fall 2%
CEO pushes customer-centric culture post-rebrand; analyst says move fails to ease competition and pricing headwinds
D1 +0.9% · +5d -8.4%
2 waves of this story
- 2026-09-14 Day-to-day name changes to Novo to boost recognition amid obesity market share loss.
- 2026-09-15 CEO pushes customer-centric culture post-rebrand; analyst says move fails to ease competition and pricing headwinds
2026-09-12 → 09-14AnalystBear
Morgan Stanley downgrades Novo to Underweight on patent, rivalry woes
MS cuts to Underweight citing muted growth, patent risks, Lilly pressure.
D1 +0.9% · +5d -8.4%
2 waves of this story
- 2026-09-12 Analysts worry semaglutide to be 75% of 2026 sales, patent cliff looms
- 2026-09-14 MS cuts to Underweight citing muted growth, patent risks, Lilly pressure.
2026-09-11Analyst
Morgan Stanley downgrades to Underweight
D1 -2.1% · +5d +0.4%
2026-09-10ProductBull
Novo Nordisk's Wegovy approved in China for MASH liver disease
First GLP-1 approved in China for MASH, expanding Wegovy's indications
D1 -1.2% · +5d -1.9%
2026-09-07 → 09-09Product
Novo's Semaglutide Hits Pediatric Obesity Goal Amid Competitive Pressures
Phase III STEP Young shows BMI reduction in obese children aged 6-12, 40.4% no longer obese; faces Lilly competition and patent cliffs
D1 -3.1% · +5d -5.8%
2 waves of this story
- 2026-09-07 Two independent reports confirm primary endpoint met in children 6-12, potentially expanding Wegovy's label
- 2026-09-09 Phase III STEP Young shows BMI reduction in obese children aged 6-12, 40.4% no longer obese; faces Lilly competition and patent cliffs
2026-09-08CompanyBear
Novo Nordisk halts two more heart drug trials, diversification setback
Two ziltivekimab trials halted, underscoring reliance on obesity franchise for growth
D1 -3.1% · +5d -5.8%
2026-09-02 → 09-03Regulation
FDA Warns on Compounded GLP-1 Risks, Novo Nordisk in Focus
FDA cites 30 firms, HIMS falls, LLY and NVO in focus
D1 +3.7% · +5d -5.9%
2 waves of this story
- 2026-09-02 FDA warning letters ban retatrutide and cagrilintide in compounding, impacting GLP-1 market
- 2026-09-03 FDA cites 30 firms, HIMS falls, LLY and NVO in focus
2026-09-01 → 09-03Product
Novo Nordisk's Oral Wegovy Launches in Germany, Zava Begins Delivery
Zava confirms delivery of oral Wegovy in Germany, aligning with EU-first launch and advancing commercialization
D1 -0.5% · +5d -1.2%
2 waves of this story
- 2026-09-01 Oral Wegovy launched in Germany, first EU country, expanding weight-loss drug market reach
- 2026-09-03 Zava confirms delivery of oral Wegovy in Germany, aligning with EU-first launch and advancing commercialization
2026-08-28AnalystBear
Deutsche Bank downgrades Novo Nordisk to Sell, shares down 70% from peak
Growth concerns mount; Wall Street had been reluctant to advise selling
D1 -1.4% · +5d +2.2%
2026-08-14 → 08-26Product
China regulator accepts oral Wegovy application; competition persists
After Lilly oral approval, Novo advances oral weight-loss drug in China
D1 -1.8% · +5d +1.9%
2 waves of this story
- 2026-08-14 Eli Lilly's Foundayo, Europe's first oral GLP-1 approval with no food restrictions, directly challenges Novo Nordisk's oral Wegovy
- 2026-08-26 After Lilly oral approval, Novo advances oral weight-loss drug in China
2026-08-10 → 08-19Company
Novo Nordisk Starts Study for Lowest Effective Wegovy Pill Dose
New study tests lower doses, potentially expanding oral weight-loss drug access
D1 +1.0% · +5d -6.0%
4 waves of this story
- 2026-08-10 Co-innovation hub in London to accelerate drug discovery
- 2026-08-11 Oral GLP-1 competition intensifies; OASIS 5 start and UK approval of Lilly's pill both impact NVO's market position
- 2026-08-11 Phase 3 trial for oral weight-loss drug expands pipeline amid competitive pressure.
- 2026-08-19 New study tests lower doses, potentially expanding oral weight-loss drug access
2026-08-12AnalystBear
Berenberg Cuts Novo Nordisk to Hold, PT Lowered to $47
Analyst sees further multiple expansion requiring proof of obesity-pill lead and injectable growth
D1 -1.7% · +5d +0.2%
2026-08-11CapitalBear
First Trust Advisors Cuts Novo Nordisk Stake by 94.5% in Q1
Institutional selling signals caution on Novo Nordisk's near-term outlook.
D1 -1.2% · +5d -3.1%
2 waves of this story
- 2026-08-11 Institutional 13F filing shows major stake reduction, reflecting institutional flows
- 2026-08-11 Institutional selling signals caution on Novo Nordisk's near-term outlook.
2026-08-08ProductBear
Eli Lilly Officially Sets Q1 2027 FDA Filing for Retatrutide, Intensifying Weight-Loss Competition
Lilly reports 28.3% average weight loss over 80 weeks in phase 3, with official filing timeline, directly pressuring Novo Nordisk
D1 +1.0% · +5d -6.0%
2 waves of this story
- 2026-08-08 Phase 3 shows 28.3% avg weight loss, outperforming rivals, posing direct threat to Novo Nordisk
- 2026-08-08 Lilly reports 28.3% average weight loss over 80 weeks in phase 3, with official filing timeline, directly pressuring Novo Nordisk
2026-08-05 → 08-08Earnings
Novo Nordisk Q2: Adjusted Sales Up 7%, GLP-1 Volume Supports but Prices Under Pressure
Earnings call reveals latest results, completing the event line with prior guidance and stock reaction
D1 +0.6% · +5d +4.2%
3 waves of this story
- 2026-08-05 Q2 profit beat and guidance hike failed to reassure, as Wegovy pill sales slightly missed and pipeline concerns persist, sending shares down over 5%.
- 2026-08-05 CEO Doustdar pledges faster R&D and bolt-on acquisitions, but investors remain cautious on pipeline confidence.
- 2026-08-08 Earnings call reveals latest results, completing the event line with prior guidance and stock reaction
2026-08-07RegulationBull
Texas Court Dismisses Strive Antitrust Suit Against Novo and Lilly
Federal judge dismisses Strive antitrust suit; NVO rises nearly 2%
D1 +2.8% · +5d -2.9%
2 waves of this story
- 2026-08-07 Court found no proof of blocked competition, easing legal overhang for Novo and Lilly.
- 2026-08-07 Federal judge dismisses Strive antitrust suit; NVO rises nearly 2%
2026-08-05Earnings
Earnings report
D1 +0.6% · +5d +4.2%

$NVO (Novo Nordisk A/S) — investor discussion on X

Five-factor rating: Sell (sector percentile 28.4%)

Recent discussion events

Most active credible voices on $NVO

Recent headlines featuring $NVO

$NVO (Novo Nordisk A/S) — investor discussion on X

Five-factor rating: Sell (sector percentile 28.4%)

Recent discussion events

Most active credible voices on $NVO

Recent headlines featuring $NVO

FDA Delays Denecimig Review on Facility Remediation; Novo Hemophilia Drug Launch Pushed Back

Lilly Oral Data Adds Pressure; Novo Nordisk Faces Intensified Obesity Competition

Novo's Ozempic 2mg Shows Lower CV Risk vs Mounjaro

Novo Nordisk inks up to $2.6B licensing deal with Hengrui for oral obesity drug

Novo Nordisk signs $1.3B licensing deal with Nanexa for injection tech

Novo Nordisk Receives Positive EU Regulatory Recommendations, Expanding Rare Disease Pipeline

Novo CEO: Pills could capture 50% of weight-loss market by 2030

CEO Open to Direct NYSE Listing to Boost US Presence

Novo Nordisk's CagriSema Shows Superior Weight Loss vs Tirzepatide in Phase 5 Trial

Novo's Denecimig Gets EU CHMP Positive Opinion

Novo Nordisk partners with Anthropic for AI-driven drug discovery

Novo Nordisk, Orbis Sign Up to $1.4B Oral Drug Deal

Lilly's Oral GLP-1 Captures 30%+ New US Patients, Pressuring Novo's Oral Share

Novo Nordisk Rebrands to Novo; CEO Urges Customer Focus, Shares Fall 2%

Morgan Stanley downgrades Novo to Underweight on patent, rivalry woes

Morgan Stanley downgrades to Underweight

Novo Nordisk's Wegovy approved in China for MASH liver disease

Novo's Semaglutide Hits Pediatric Obesity Goal Amid Competitive Pressures

Novo Nordisk halts two more heart drug trials, diversification setback

FDA Warns on Compounded GLP-1 Risks, Novo Nordisk in Focus

Novo Nordisk's Oral Wegovy Launches in Germany, Zava Begins Delivery

Deutsche Bank downgrades Novo Nordisk to Sell, shares down 70% from peak

China regulator accepts oral Wegovy application; competition persists

Novo Nordisk Starts Study for Lowest Effective Wegovy Pill Dose

Berenberg Cuts Novo Nordisk to Hold, PT Lowered to $47

First Trust Advisors Cuts Novo Nordisk Stake by 94.5% in Q1

Eli Lilly Officially Sets Q1 2027 FDA Filing for Retatrutide, Intensifying Weight-Loss Competition

Novo Nordisk Q2: Adjusted Sales Up 7%, GLP-1 Volume Supports but Prices Under Pressure

Texas Court Dismisses Strive Antitrust Suit Against Novo and Lilly

Earnings report